Skip to content

AI Vivo

Combining systems phar­ma­cology and AI to accelerate drug discovery

First Investment: 2019

Current-day drug discovery is inefficient because the focus on molecular targets misses the underlying cellular- and tissue-level dynamics of disease. AI Vivo’s Organome technology ranks drug candidates based on their phenotypic effects at the tissue level. In 2020 the company’s platform correctly predicted that dexam­etha­sone, a commonly prescribed steroid, would save the lives of Covid-19 patients 10 weeks before researchers publicized this outcome.

Explore Companies